A randomised, controlled, open-label, 48-week, study to asses differences in changes in plasma lipid profile between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine as a first-line regimen.

Trial Profile

A randomised, controlled, open-label, 48-week, study to asses differences in changes in plasma lipid profile between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine as a first-line regimen.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Saquinavir (Primary) ; Atazanavir/ritonavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms BASIC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Dec 2009 Results reported at 12th European AIDS Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top